Aardvark Therapeutics Inc. (AARD) announced that it has voluntarily paused the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO study is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS).
The decision to pause both the HERO trial and its open-label extension was based on reversible cardiac observations at above-target therapeutic doses identified during routine safety monitoring in a healthy volunteer study. Aardvark is conducting a comprehensive review of the data to determine next steps. Out of caution, the company has suspended ongoing enrollment and dosing in the HERO trial while this evaluation is underway.
As a result of these developments, Aardvark no longer expects to announce topline data from the HERO trial in the third quarter of 2026. Instead, the company plans to provide updated guidance in the second quarter of this year, once the review of the ARD-101 program is complete.
Aardvark Therapeutics shares closed the regular trading session at $12.49, down $0.01 or -0.08% as of 4:00:03 PM EST. In after-hours trading, the stock experienced a sharp decline, falling to $6.58, a drop of $5.91 or -47.32% as of 7:59:37 PM EST.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.